Blood Factors and Diabetic Retinopathy

Sponsor
National Eye Institute (NEI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00005761
Collaborator
(none)
173
1
126.5
1.4

Study Details

Study Description

Brief Summary

This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy.

Patients age 10 years and older with diabetes mellitus and diabetic retinopathy may be eligible for this study. Those enrolled will represent a range of diabetic retinopathy from minimal to severe. Participants will undergo the following procedures:

  • medical history

  • thorough eye examination

  • photographs of the eye

  • blood tests to measure blood lipids (cholesterol and triglycerides) and serum creatinine (for kidney function)

  • blood tests to measure levels of blood factors (cell adhesion molecules, chemokines and vascular endothelial growth factor) that may be related to the progression of diabetic retinopathy

  • blood pressure measurement

  • urinalysis

This study may lead to a better understanding of how diabetic retinopathy develops and progresses.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Participants with a range of severity of diabetic retinopathy and healthy volunteers will be evaluated once for serum levels of cell adhesion molecules, chemokines and vascular endothelial growth factor. This study may lead to a better understanding of the pathogenesis of diabetic retinopathy and the identifying of possible targets for treatment. All study participants will undergo an ocular exam and ophthalmic photography. Blood is drawn for the analysis of these serum factors.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    173 participants
    Official Title:
    Study of Association of Serum Factors With Diabetic Retinopathy
    Study Start Date :
    May 23, 2000
    Study Completion Date :
    Dec 7, 2010

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      10 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      • VOLUNTEER INCLUSION CRITERIA:
      Volunteers will be able to enroll if they:
      • Have the ability to understand and sign an informed consent.

      • Are able and willing to give a blood sample.

      • Are healthy as determined by study Investigator.

      • Have no chronic diseases.

      • Do not exhibit any clinical indications of diabetes.

      PARTICIPANT INCLUSION CRITERIA:
      Participants will be able to enroll if they:
      • Have the ability to understand and sign an informed consent.

      • Are able and willing to give a blood sample.

      • Have a clinical diagnosis of diabetes based on any one of the following criteria:

      1. Documented history of plasma glucose value greater than or equal to 210 mg/dl on three different occasions.

      2. Fasting blood sugar greater than or equal to 150 mg/dl on three different occasions.

      3. Documented history of ketoacidosis.

      4. Insulin dependency.

      5. Documented history of abnormal glucose tolerance test.

      EXCLUSION CRITERIA:
      Neither volunteers nor participants will be eligible if they:
      • Are under the age of 10.

      • Have severe systemic disease(s) that compromise our ability to obtain an adequate examination.

      • Have any of the following ocular characteristics or conditions in both eyes:

      1. Opacities of the ocular media, limitations or pupillary dilation or any other problems sufficient to preclude good, quality stereo fundus photographs.

      2. Ocular disease which confounds assessment of diabetic retinopathy such as advanced age-related macular degeneration, central serous choroidopathy, optic atrophy, retinal vein occlusion, active uveitis, significant explained or unexplained visual field loss, or any other type of retinopathy or retinal degeneration.

      3. Chronic requirement for any ocular medication for other diseases, such as glaucoma.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

      Sponsors and Collaborators

      • National Eye Institute (NEI)

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00005761
      Other Study ID Numbers:
      • 000135
      • 00-EI-0135
      First Posted:
      May 29, 2000
      Last Update Posted:
      Jul 2, 2017
      Last Verified:
      Dec 7, 2010

      Study Results

      No Results Posted as of Jul 2, 2017